RE:RE:Roche in-licenses USP-1 small molecule to PARP inhibitorThe IRA also sets out differential treatment for large molecule versus small molecule products, with injectables being better insulated from the the Drug Price Negotiation Program (DPNP) than pills. Large molecule drugs cannot be selected for DPNP for 13 years from the date of their FDA approval, whereas small molecule drugs can be selected after 9 years from the date of their FDA approval.